Purpose The purpose of this study was to determine whether specific HOXA epigenetic signatures could dif- ferentiate glioma with distinct biological, pathological, and clinical characteristics. Methods We evaluated HOXA3, 7, 9, and 10 methylation in 63 glioma samples by MassARRAY and pyrosequencing. Results We demonstrated the direct statistical correlation between the level of methylation of all HOXA genes examined and WHO grading. Moreover, in glioblastoma patients, higher level of HOXA9 and HOXA10 methylation significantly cor- related with increased survival probability (HOXA9—HR: 0.36, P = 0.007; HOXA10—HR: 0.46, P = 0.045; combined HOXA9 and 10—HR 0.28, P = 0.004). Conclusions This study identifies HOXA3, 7, 9, and 10 as methylation targets mainly in high-grade glioma and hypermethylation of the HOXA9 and 10 as prognostic factor in glioblastoma patients. Our data indicate that these epigenetic changes may be biomarkers of clinically dif- ferent subgroups of glioma patients that could eventually benefit from personalized therapeutic strategies.
Di Vinci, A., Casciano, I., Marasco, E., Banelli, B., Ravetti, G.l., Borzì, L., et al. (2012). Quantitative methylation analysis of HOXA3, 7, 9, and 10 genes in glioma: association with tumor WHO grade and clinical outcome. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 138, 35-47 [10.1007/s00432-011-1070-5].
Quantitative methylation analysis of HOXA3, 7, 9, and 10 genes in glioma: association with tumor WHO grade and clinical outcome
MARASCO, ELENA;MANTOVANI, VILMA;
2012
Abstract
Purpose The purpose of this study was to determine whether specific HOXA epigenetic signatures could dif- ferentiate glioma with distinct biological, pathological, and clinical characteristics. Methods We evaluated HOXA3, 7, 9, and 10 methylation in 63 glioma samples by MassARRAY and pyrosequencing. Results We demonstrated the direct statistical correlation between the level of methylation of all HOXA genes examined and WHO grading. Moreover, in glioblastoma patients, higher level of HOXA9 and HOXA10 methylation significantly cor- related with increased survival probability (HOXA9—HR: 0.36, P = 0.007; HOXA10—HR: 0.46, P = 0.045; combined HOXA9 and 10—HR 0.28, P = 0.004). Conclusions This study identifies HOXA3, 7, 9, and 10 as methylation targets mainly in high-grade glioma and hypermethylation of the HOXA9 and 10 as prognostic factor in glioblastoma patients. Our data indicate that these epigenetic changes may be biomarkers of clinically dif- ferent subgroups of glioma patients that could eventually benefit from personalized therapeutic strategies.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
